Patents Assigned to Sun Pharma Advanced Research Company Ltd.
-
Patent number: 11951106Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.Type: GrantFiled: June 17, 2021Date of Patent: April 9, 2024Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Ajay Jaysingh Khopade, Arindam Halder
-
Patent number: 11931359Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.Type: GrantFiled: December 5, 2022Date of Patent: March 19, 2024Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Ajay Jaysingh Khopade, Arindam Halder
-
Publication number: 20240066014Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 11, 2023Publication date: February 29, 2024Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
-
Patent number: 11813252Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 18, 2022Date of Patent: November 14, 2023Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji Damle, Sanjay Nandlalji Mandhane, Manoj Atmaramji Upadhya, Sameer Vishwanath Mehetre, Gajanan Uttamrao Chidrewar, Prabal Sengupta, Trinadha Rao Chitturi
-
Patent number: 11583522Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 1, 2020Date of Patent: February 21, 2023Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji Damle, Sanjay Nandlalji Mandhane, Manoj Atmaramji Upadhya, Sameer Vishwanath Mehetre, Gajanan Uttamrao Chidrewar, Prabal Sengupta, Trinadha Rao Chitturi
-
Patent number: 11465990Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.Type: GrantFiled: October 28, 2020Date of Patent: October 11, 2022Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Ranjan Kumar Pal, Amit Pravinbhai Sedani, Kaushikkumar Dhanjibhai Prajapati, Dijixa Pinakin Rana, Sandeep Pankajbhai Pathak, Japan Nitinkumar Desai, Jayraj Dilipbhai Aradhye, Bhavesh Mohanbhai Panchal, Indraneel Ghosh, Trinadha Rao Chitturi
-
Publication number: 20220273632Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 18, 2022Publication date: September 1, 2022Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
-
Patent number: 11304898Abstract: A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.Type: GrantFiled: June 8, 2016Date of Patent: April 19, 2022Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTDInventors: Wen Wee Ma, Alex Adjei, Lynne Bui, Ronald Harning, Ajay Khopade, Subhas Bhowmick, Natarajan Arulsudar, Narendra Lakkad
-
Patent number: 11241443Abstract: The present invention relates to an ophthalmic solution comprising (i) bimatoprost or its pharmaceutically acceptable salt in an amount ranging from about 0.005% to 0.015% weight by volume; (ii) a biguanide compound in an amount ranging from about 0.003% to 0.05% weight by volume; (iii) an acylated amino acid in an amount ranging from about 0.01% to 0.1% weight by volume; (iv) pharmaceutically acceptable excipients and (v) purified water.Type: GrantFiled: April 7, 2018Date of Patent: February 8, 2022Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Ajay Jaysingh Khopade, Arindam Halder
-
Patent number: 11225480Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.Type: GrantFiled: October 16, 2020Date of Patent: January 18, 2022Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTDInventors: Gaurav Sanjivkumar Sheth, Sabbirhusen Yusufbhai Chimanwala, Tushar Mukund Jarag, Aishwarya Hampiholi, Saikat Maity, Prabal Sengupta, Gulamnizami Abdulsattar Qureshi, Umesh Vishnu Chaudhari, Raj Gopal Venkat, V. S. N. Murty Kadiyala, Sairam V V M Kalapatapu, Vaibhav Jain, Trinadha Rao Chitturi
-
Publication number: 20210137921Abstract: A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.Type: ApplicationFiled: January 25, 2021Publication date: May 13, 2021Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Bhalachandra DHARMADIKARI, Yashoraj R. ZALA, Ashwini GADKARI
-
Publication number: 20210015805Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 1, 2020Publication date: January 21, 2021Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
-
Patent number: 10849887Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3, alkyl, C1-3, haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 2, 2017Date of Patent: December 1, 2020Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji Damle, Sanjay Nandlalji Mandhane, Manoj Atmaramji Upadhya, Sameer Vishwanath Mehetre, Gajanan Uttamrao Chidrewar, Prabal Sengupta, Trinadha Rao Chitturi
-
Publication number: 20200000803Abstract: A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.Type: ApplicationFiled: September 13, 2019Publication date: January 2, 2020Applicant: Sun Pharma Advanced Research Company Ltd.Inventors: Nitin Bhalachandra Dharmadikari, Yashoraj Zala, Ashwini Gadkari
-
Patent number: 10512608Abstract: The present invention relates to a nanoparticulate topical composition comprising (i) nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm, (ii) one or more wetting agent and (iii) a non-aqueous liquid vehicle, wherein the composition is free of water. The present invention also relates to a method of treating acne, rosacea, impetigo or a skin disease caused by a bacteria, by topical application of a nanoparticulate topical composition comprising nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm.Type: GrantFiled: February 25, 2016Date of Patent: December 24, 2019Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Madhusudhan Bommagani, Subhas Balaram Bhowmick, Prashant Kane, Vaibhav Dubey
-
Patent number: 10413543Abstract: A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.Type: GrantFiled: February 12, 2016Date of Patent: September 17, 2019Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Bhalachandra Dharmadikari, Yashoraj Zala, Ashwini Gadkari
-
Publication number: 20190275017Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3, alkyl, C1-3, haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 2, 2017Publication date: September 12, 2019Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
-
Patent number: 10226428Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a swellable composition located in an immediate vicinity of one or more preselected surfaces. The coating comprises a defect wherein said defect is not a passageway through the preselected portion of the coating and operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.Type: GrantFiled: September 10, 2012Date of Patent: March 12, 2019Assignee: Sun Pharma Advanced Research Company Ltd.Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala, Amarjit Singh
-
Patent number: 10213387Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.Type: GrantFiled: September 10, 2012Date of Patent: February 26, 2019Assignee: Sun Pharma Advanced Research Company Ltd.Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala, Amarjit Singh
-
Patent number: 10172852Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.Type: GrantFiled: July 24, 2015Date of Patent: January 8, 2019Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Ajay Jaysingh Khopade, Arindam Halder